In this pilot study, we evaluated the anatomical, functional efficacy and safety of a combined treatment with DXI and anti-VEGF in patients with wet-AMD and persistent retinal fluid despite conventional treatment. The gene discussed is VEGFA; the disease is age-related macular degeneration.